Quality Connection is a labor management partnership comprised of 100 union electrical contractors and nearly 3,000 International Brotherhood of Electrical Workers (IBEW) #481 electrical workers. Together labor and management provide the needed expertise, highly trained workforce, safety and dedication to help build many of Central Indiana’s premiere education, health care, utility sites and logistics projects. The unique business relationship spans more than 50 years and represents a strong tradition of quality electrical construction, progressive labor negotiations and community service. With an unprecedented commitment to workforce training, job safety and worker standards. Quality Connection . . .Quality Work, Customer Connected. Learn more at www.qcindy.com
One of the most effective chemotherapeutics used in the treatment of cancer continues to be the DNA damaging agent cisplatin. Pioneered by our Medical Advisor, Dr. Larry Einhorn at the Indiana University School of Medicine for the treatment of testicular cancer, cure rates now exceed 90% for this cancer. This represents one of the few shining stories since the “War on Cancer” was initiated in the early 1970’s. Unfortunately, cisplatin is considerably less effective in treating other cancers but remain first-line treatment for lung and ovarian cancer. NERx Biosciences co-founder and CSO, Dr. John Turchi has been studying the biology and biochemistry of cisplatin for 25 years and in 2005 was recruited to the Indiana University Cancer Center where advances in his laboratory have paved the way for recapitulating the successes of platinum treatment for testicular cancer in lung and ovarian cancer.
NĒRx Biosciences was established in 2009 to capitalize on these advances and discoveries to develop novel therapeutics to enable the effective treatment of highly prevalent and difficult to treat cancers including lung and ovarian. Learn more at www.nerxbiosciences.com.
Researching and developing advanced process technology and design manufacturing plan cooperated with Futago LLC.
KinaSense is developing cell-based assays used in preclinical drug discovery to identify and characeterize new compounds for oncology. Our assays are faster, less expensive, and have more physiological relevance than traditional methods used in target validation and potency studies, allowing earlier decision making fro progressing compounds into animal studies.Learn more at www.kinasense.com.
MorNuCo, Inc. is a biotech company focused on age related diseases with an emphasis on cancer detection. Learn more at www.mornuco.com.
Phytoption LLC is an innovation company developing propriatory ingredients to improve drug bioavailability, food quality, and cosmetics functionality. It offers patented technology and ingredients to pharmaceutical, food, or cosmetic industrial partners.
Safekeeping is a moblie application that delivers health and lifestyle information to family members of patients in care facilities.Learn more at www.safekeepingapp.com.